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Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difﬁcult to predict. We evaluated collagen pro-
portionate area (CPA), a quantitative histological index, at 1 year with respect to the ﬁrst episode of clinical decompensa-
tion. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples
stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables
associated with ﬁrst appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also
used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1 year, median CPA was 4.6% (0.2%-
36%) and Ishak stage was 0-2 in 101 patients, 3-4 in 23 patients, and 5-6 in 11 patients. Decompensation occurred in 26
(19.3%) at a median of 61 months (15-138). Univariately, CPA, tacrolimus monotherapy, and Ishak stage/grade at 1 year
were associated with decompensation; upon multivariate analysis, only CPA was associated with decompensation (P ¼
0.010; Exp(B) ¼ 1.169; 95%CI, 1.037-1.317). Area under the ROC curve was 0.97 (95%CI, 0.94-0.99). A cutoff value of
6% of CPA had 82% sensitivity and 95% speciﬁcity for decompensation. In the 89 patients with hepatic venous pressure
gradient (HVPG) measurement, similar results were obtained. When both cutoffs of CPA > 6% and HVPG  6 mm Hg
were used, all patients decompensated. Thus, CPA at 1-year biopsy after liver transplantation was highly predictive of clini-
cal outcome in patients infected with hepatitis C virus who underwent transplantation, better than Ishak stage or HVPG.
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Evaluation of liver ﬁbrosis remains one of the
most important aspects in chronic liver disease.
Histological assessment of ﬁbrosis is still the
reference standard1 for the evaluation of new antiﬁ-
brotic treatments and for validation of noninvasive
markers of ﬁbrosis, as well as other established
prognostic markers such as hepatic venous pressure
gradient (HVPG).2,3
Currently, all histological scoring systems use a cat-
egorical system that includes description of architec-
tural changes as well as the location of ﬁbrosis. They
do not assess quantitative changes of ﬁbrosis.1
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Indeed, METAVIR and/or Ishak systems assign num-
bers to categories that are not quantitatively related,
nor are they continuous variables. Applying these ﬁ-
brosis stage scores as numerical data in statistics is
incorrect and misleading.1 The development and use
of a novel histological index that quantitates ﬁbrosis
and relates to clinical outcome would greatly improve
the value of liver biopsy.
Optimal assessment of such a novel index could be
performed in patients with hepatitis C virus (HCV)-
derived cirrhosis after liver transplantation (LT),
because often in this population there is rapid ﬁbro-
sis, early cirrhosis, and decompensation.4-6 In this
setting, survival is worse compared to other indica-
tions after LT.7 Because the course of HCV reinfection
and decompensation is unpredictable, prediction of
rapid ﬁbrosis would be clinically useful regarding the
potential to start antiviral treatment earlier and to
prevent decompensation.
We have developed a method using computer-
assisted digital image analysis (DIA) using sirius red–
stained histological sections which can quantify liver
collagen.1,8 The quantity of PicroSirius red correlates
well with morphometrically calculated hepatic ﬁbro-
sis.9 Previous studies have shown that morphometric
image analysis had better sensitivity than histological
staging in evaluating ﬁbrosis progression10 in 245
patients treated for chronic hepatitis C. However,
when morphometric image analysis was used in the
literature, the amount of collagen was not expressed
as a simple proportionate area. A presumed histologi-
cal section thickness was used in order to calculate
the quantity of collagen.10,11 In our method, segmen-
tation of digital images measure the area of collagen
and of tissue, producing a ‘‘ﬁbrosis ratio’’ or collagen
proportionate area (CPA).1,12
More recently, we showed that CPA assessment in
HCV-infected post-LT patients correlated with both
Ishak stage scores and HVPG. However, CPA was a
better histological correlate with HVPG than with
Ishak stage, with greater percentage changes in CPA
than in HVPG in early portal hypertension (HVPG > 6
mm Hg but  10 mm Hg).12 Moreover, CPA was the
only independent histological variable associated with
both early portal hypertension and clinically signiﬁ-
cant portal hypertension (HVPG > 10 mm Hg).12
Therefore, the aim of this study was to evaluate
CPA measured in liver biopsies of patients at 1 year
after transplantation for HCV-related cirrhosis, with
respect to the ﬁrst episode of clinical decompensation.
By searching the literature, we also correlated CPA
with HVPG and other known factors associated with
severity of ﬁbrosis due to recurrent HCV.
PATIENTS AND METHODS
Between October 1988 and October 2008, 257
patients underwent transplantation at the Royal Free
Hospital, London, UK, with end-stage liver disease
due to HCV infection (278 transplants): 135 patients
with ﬁrst transplant who had a follow-up of at least
12 months were assessed for CPA at 1-year biopsy
(performed between 12-15 months) and evaluated for
factors that could predict clinical decompensation. Of
the 122 patients excluded from our study, 41 died
before 1-year post-LT biopsy, 15 had less than 12
months follow-up, 6 were followed up in other centers,
4 were lost to follow-up, 22 had insufﬁcient stored bi-
opsy material, and 34 were assessed for CPA but not
within 12-15 months after LT. From these 135
patients, 89 had their transjugular liver biopsy com-
bined with HVPG measurement (started in February
1999). We performed a second separate analysis for
the prediction of clinical decompensation in the 89
patients with HVPG measurement.
For each patient, demographic and clinical data
(listed in Tables 1 and 2), donor age and sex, cold and
warm ischemia time, initial and 1-year post-LT immu-
nosuppression, characteristics and treatment of rejec-
tion episodes, the year of transplantation (divided into
3 eras, n1 ¼ 1988-1994, n2 ¼ 1995-2000, n3 ¼ 2001-
2008), cytomegalovirus (CMV) post-LT infection or
any other infection, histological episodes of acute hep-
atitis, genotype, viral load pre-LT, and 1 year post-LT,
diabetes mellitus pretransplant and posttransplant,
human leukocyte antigen (HLA), and blood group
compatibility of donor and recipient were recorded. All
of the above variables as well as liver function tests at
1-year biopsy were evaluated in the univariate analy-
sis along with CPA, HVPG, and stage and grade
according to Ishak at 1 year, for the prediction of clin-
ical decompensation.
Clinical decompensation was deﬁned as the ﬁrst
occurrence of clinical manifestation of ascites/hydro-
thorax, variceal bleeding, jaundice (3 mg/dL, in the
absence of other causes), or encephalopathy.
The study protocol conformed to the ethical guide-
lines of the Declaration of Helsinki. All patients gave
written informed consent for both the procedure and
the histological evaluation.
Liver Biopsies
Liver biopsy samples were formalin-ﬁxed, parafﬁn-
embedded, and stained with hematoxylin and eosin,
Gordon and Sweet staining for reticulin, and chromo-
trope aniline blue. Another tissue section was stained
with PicroSirius red for collagen quantiﬁcation and
determination of CPA by DIA. For each biopsy sample,
there was histological evaluation for the stage of dis-
ease (ﬁbrosis: 0-6) and the degree of necroinﬂamma-
tory activity (grade: after combining the scores for
piecemeal necrosis 0-4, conﬂuent necrosis 0-6, focal
necrosis 0-4, and portal inﬂammation 0-4) according
to Ishak et al.13
We recorded the number of liver fragments in each
biopsy and its total length (lengths of each fragment
summed), and the number of portal tracts per frag-
ment and in total.14 We excluded liver biopsies less
than 12 mm long. Portal tracts were deﬁned according
to Crawford et al.,15 which is ‘‘focus of connective
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tissue containing at least 2 luminal structures (ei-
ther/or bile duct, portal vein, or hepatic artery).’’ A
portal tract was considered complete when its full cir-
cumference was visible or when at least three-quar-
ters of the circumference and 3 luminal structures
were visible. A portal tract was considered partial
when its circumference was incomplete but contained
at least 2 luminal structures. Portal tracts were not
counted in biopsies with severe distortion of the liver
architecture, such as in cirrhosis or severe nodular
expansion, because it is impossible to recognize and
count individual portal tracts in such cases.
The sections of each biopsy stained with PicroSirius
red were used for DIA, which was performed by 2
authors blinded to each other’s results and blinded to
clinical information at that time (P.M. and G.I.), which
in addition was a means to assess interobserver error.
Interobserver variability was assessed by repeating
the CPA measurements whenever there was a differ-
ence greater than 2% between the 2 assessors. The
equipment used and the CPA measurement was per-
formed as described.12
Acute cellular rejection (ACR) was graded using the
Royal Free Hospital (RFH) score.16 An RFH score 4
established the diagnosis of ACR; if >7, rejection was
treated. Corticosteroid-resistant cellular rejection was
deﬁned if there was no histological improvement in a
biopsy 5 days after the ﬁrst, despite intravenous
methylprednisolone administered at 1 g daily for 3
days.
TABLE 1. Patient Characteristics With Respect to Future Clinical Decompensation or Not
Patients
Future
Decompensation (27) No Decompensation (108) P Value
Recipient Age 53.8 51.5 NS
Males 69% 76% NS
Donor Age 43.7 (16-73) 38.6 (11-69) 0.1
Year of LT 88-94/95-00/
01-08 (%)
19%/44%/37% 12%/37%/51% NS
Concomitant ALD % 15% 24% NS
Cold/warm ischemia* Minutes 680/46 678/41 NS
Diabetes pre/post-LT % 23%/23% 25%/25% NS
BMI pre-LT Median (kg/m2) 29.2 (22-34) 28 (21-34) NS
Viral load pre-LT Median 2.72  106 1.73  106 NS
Viral load 1 year post-LT Median 4  106 2.8  106 0.1
Genotype 1 % 55% 42% 0.1
Patients treated n 13 (48%)† 20 (19%) 0.3
SVR (censored)‡ 3 (23%) 8 (40%)
CMV infection % 21% 13% NS
Histological AHC % 54% 23% 0.015
ACR episodes 0/>2 35%/19% 16%/20% 0.1
Initial
immunosuppression
TAC/CYA/SIR 62%/39%/0%
(42% TAC mono)
72%/25%/0.9%
(27% TAC mono)
0.05
Steroids 54% 60% NS
AZA/MMF 46%/8% 59%/8% NS
Maintain
immunosuppression
TAC/CYA/SIR 54%/23%/11% 67%/19%/10% NS
Steroids 11% 5% NS
AZA/MMF 11%/19% 23%/22% 0.1
Follow-up months 73 (14-138) 77 (15-191) NS
*Cold ischemia time: interval from donor cross-clamp to removal from cold storage/warm ischemia time: interval between
removal from cold storage and venous reperfusion.
†A total of 6 of 13 were treated after decompensation.
‡Censored at time of SVR.
P values refer to the univariate analysis.
TABLE 2. Histological Characteristics and HVPG at the Time of Biopsy, 1 Year After Liver Transplantation
Patients
Future
Decompensation (27) No Decompensation (108) P Value
Ishak stage* 0-2/3-4/5-6 (%) 26/37/37 87/12/1 <0.001
Ishak grade* 0-6/7-12/13-18 (%) 33/63/4 85/15/0 0.001
CPA* % median (range) 11.9 (0.7-36) 2.9 (0.20-10) <0.001
HVPG measured n (%) 22 (81%) 67 (62%) NS
HVPG* mm Hg median (range) 7 (4-16) 4 (1-9) <0.001
180 MANOUSOU ET AL. LIVER TRANSPLANTATION, February 2011
Acute hepatitis C (AHC) was diagnosed when ala-
nine aminotransferase levels increased 2 times
upper normal limit, together with histological changes
consistent with hepatitis, ie, predominantly lobular
inﬂammation and/or scattered parenchymal apopto-
sis, without diagnostic features of cellular rejection,
bile duct loss, or other cause of liver injury.17
Hemodynamic Studies
HVPG was measured using standard techniques14,18
associated with transjugular biopsy in 89 patients of
135 included in our study. Clinically signiﬁcant portal
hypertension was deﬁned as HVPG  10 mm Hg.19-22
Virological Assays and Antiviral Therapy
Serum samples before transplant and at the time of
1-year liver biopsies, were collected, stored at 70C,
and analyzed for HCV RNA by polymerase chain reac-
tion; HCV genotype was evaluated as described.17 At
RFH, CMV viremia was screened for by polymerase
chain reaction assay initially qualitatively thrice
weekly, and then quantitatively twice weekly.23
Patients were considered for off-label antiviral HCV
therapy of pegylated interferon and ribavirin if stage 4
ﬁbrosis due to recurrent HCV is reached.
Immunosuppression Regimens
In our center, maintenance immunosuppression regi-
mens have changed over the years. Cyclosporine-
based immunosuppression changed to tacrolimus-
based immunosuppression following the results of the
TMC study.24 Before this study, a cohort received cal-
cineurin inhibitor monotherapy25 with either cyclo-
sporine (CYA) or tacrolimus (TAC). After the TMC
study, patients received triple immunosuppression
therapy with corticosteroids, TAC and azathioprine
(AZA), or TAC monotherapy while participating in a
randomized trial of TAC monotherapy versus triple
therapy.26 Steroids were tapered within 3 months if
possible. Patients who received steroids for more than
3 months (mainly indicated because of repeated rejec-
tion episodes) were deﬁned as those with long-term
steroid maintenance therapy. Mycophenolate mofetil
(MMF) was used to substitute AZA if there was intol-
erance to AZA or renal dysfunction.
TAC (Prograf; Fujisawa, Ltd., Killorglin, County
Kerry, Ireland) administered at 0.1 mg/kg/day or CYA
at 10 mg/kg/day was given nasogastrically in 2 di-
vided doses, starting within 6 hours from transplanta-
tion. AZA was given intravenously then orally, at 1
mg/kg/day, and methylprednisolone (16 mg/day
intravenously) until oral intake was established, when
20 mg/day prednisolone was used. If poor renal and/
or graft function was present, TAC dosing (evaluated
every other day) was adjusted according to clinical
progress or occurrence of adverse effects, with the
aim to maintain a whole-blood level of 5-10 ng/mL as
determined by microparticle enzyme immunoassay
(ImxTacrolimus II; Abbott Laboratories, Abbott Park,
IL). CYA dose was adjusted in order to maintain
trough whole-blood levels between 150-200 ng/mL
initially and 100-150 ng/mL thereafter. AZA dose was
not changed unless neutropenia developed. Predniso-
lone was gradually tapered from 3 weeks and then
stopped between 3 and 6 months.
Acute rejection episodes were treated with 1 g daily
methylprednisolone for 3 days, given intravenously. If
rejection reoccurred and was not satisfactorily
resolved by 1 further cycle of 1 g daily methylpredni-
solone for 3 days, it was considered as steroid-resist-
ant rejection and was treated with lymphocyte anti-
bodies Orthoclone (OKT-3) or antithymocyte globulin
(ATG).
Statistical Analysis
All data were analyzed using the statistical package
SPSS (version 13.0; SPSS Inc., Chicago, IL). The chi-
square test was used for comparing quantitative vari-
ables. Quantitative variables normally distributed
were expressed as mean values 6 1 standard devia-
tion and non-normally distributed as median values
(range). Signiﬁcance testing was set to P ¼ 0.05.
Patients were censored at death, last follow-up,
retransplant, or if sustained virologic response (SVR)
was achieved.
Cox regression analysis was used to determine fac-
tors associated with clinical decompensation. The
Kaplan-Meier method was used to plot curves for
each variable that was statistically signiﬁcant in the
multivariate analysis. Time to decompensation was
deﬁned as the time from transplantation to the ﬁrst
episode of decompensation. For those with no decom-
pensation, the interval to last follow-up or death was
used as the observation interval.
We also evaluated area under the receiver operating
curve (AUROC) of the prediction of clinical decompen-
sation using CPA, stage according to Ishak, and
HVPG cutoffs. The best cutoff of the curve (Youden
index) was determined by the software program.
RESULTS
Follow-up for the 135 patients was for a median of 76
months (15-191). The median recipient age was 52
years (21-66) and 101 of the patients were male
(75%); median donor age was 41 years (16-70); 48%
had genotype 1, 31% had genotype 3, and 6 donors
had concomitant hepatitis B virus (HBV) infection.
Antiviral therapy for HCV was given in 39 patients (17
within 12 months post-LT), and 11 achieved SVR (2
within 12 months post-LT). The 6 with HBV had HBV
DNA completely suppressed. CMV infection was diag-
nosed and treated in 19 patients. A total of 39 had an
episode of acute hepatitis. A total of 19% had no epi-
sodes of acute rejection, 37% had 1 episode, 24% had
2, and 20% had more than 2 episodes.
We reviewed 135 biopsies at 1 year after LT. The
median length was 20 mm (mean, 21 mm; range, 12-
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45); 112 of the liver biopsies were 15 mm or longer.
The median number of portal tracts was 12 (range, 4-
22). In 5 biopsies (3.7%), the portal tracts were not
counted because of cirrhosis or severe nodularity.
At 1 year, median CPA was 4.63% (range, 0.2%-
36%). The stage according to Ishak was 0-2 in 101
patients, 3-4 in 23 patients, and 5-6 in 11 patients,
whereas Ishak grade was 0-6 in 92 patients, 7-12 in
16 patients, and 13-18 in 1 patient.
During follow-up, 26 patients decompensated
(19.3%) at a median of 61 months (range, 15-138
months); 10 patients presented with ascites and/or
hydrothorax, 5 with variceal bleeding, 6 with porto-
systemic encephalopathy, and 5 with jaundice.
Patients’ characteristics with respect to compensated/
decompensated groups are shown in Tables 1 and 2.
Death occurred in 33 patients (24.4%) at a median of
74 months (15-165 months), 11 from causes related
to decompensation and 22 unrelated.
Univariate and Multivariate Analysis
All the demographic and clinical data listed in Tables
1 and 2 were evaluated: 10 variables (P close or  0.1)
which resulted from the univariate analysis were
included in the Cox regression analysis for the predic-
tion of decompensation: CPA, stage and grade accord-
ing to Ishak at 1-year biopsy, ACR episodes, histologi-
cal episodes of AHC, viral load at 1 year post-LT,
donor age, genotype 1, initiation with TAC monother-
apy, and AZA use at 1 year post-LT.
In the univariate analysis, grade (P ¼ 0.01) and
stage (P < 0.001) according to Ishak, AHC (P ¼
0.015), TAC monotherapy (P ¼ 0.05), and CPA (P <
0.001) at 1-year biopsy were associated with clinical
decompensation. However, multivariate analysis by
Cox regression revealed that the only factor associated
with the prediction of clinical decompensation was the
CPA measurement (P ¼ 0.001; Exp(B) ¼ 1.148; 95%
conﬁdence interval [CI], 1.098-1.200). The receiver
operating characteristics (ROC) curve of CPA for the
prediction of decompensation is shown in Fig. 1. The
AUROC was 0.965 (95%CI ¼ 0.936-0.994). A cutoff
value of 6% of CPA had an 82% sensitivity and 95%
speciﬁcity for clinical decompensation and the highest
Youden index. Kaplan-Meier curves of CPA  6% and
CPA > 6% with respect to the prediction of decompen-
sation are shown in Fig. 1: 102 patients had CPA 
6%, 5 were decompensated (5%), whereas 22 of 33
patients with CPA > 6% were decompensated (67%).
Relationship Between CPA and Ishak Stage
As we have already described,12 CPA values increased
with worsening Ishak stage. The best cutoff of CPA
was 6% for signiﬁcant ﬁbrosis (Ishak stage > 2),
whereas for severe ﬁbrosis (Ishak stage 5 and 6), the
best cutoff value was 9%. Indeed, in this cohort of
135 patients, we conﬁrmed the relationship between
CPA values and the categories of stage (Fig. 2): stage
0 with median CPA values of 2% (interquartile range
[IQR], 1.4%-5.35%; range, 0.40%-6.30%), stage 1 with
median CPA of 2.4% (IQR, 1.6%-3.15%; range, 0.30%-
18%), stage 2 with median CPA of 3.7% (IQR, 1.35%-
4.7%; range, 0.20%-10%), stage 3 with median CPA of
4.7% (IQR, 2.02%-7.8%; range, 1.10%-23%), stage 4
with median CPA of 6.2% (IQR, 2.9%-11.4%; range,
2.80%-13.20%), stage 5 with median CPA of 9.9%
(IQR, 7.025%-20.075%; range, 2.70%-36%) and stage
6 with median CPA of 21.7% (range, 15.80%-23%). As
Figure 1. ROC curve of CPA for the prediction of clinical decompensation and Kaplan-Meier curve of CPA  6% and >6% with respect
to the prediction of clinical decompensation (chi-square ¼ 46.6, P < 0.001), in 135 patients with recurrent HCV, biopsied 1 year after
liver transplantation. AUROC is 0.965 (95%CI, 0.936-0.994). At a cutoff value of 6% of CPA, there was 82% sensitivity and 95%
specificity for clinical decompensation and the highest Youden index.
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expected, there was a relationship between CPA val-
ues and stage with the correlation coefﬁcient being r
¼ 0.600, P < 0.001.
Regarding Ishak stage, with respect to future
decompensation, 4.2% (2/48) of patients decompen-
sated with Ishak stage 1 at 1-year biopsy, 12.2% (5/
41) decompensated with Ishak stage 2, 37.5% (6/16)
with Ishak stage 3, 57% (4/7) with stage 4, 87.5% (7/
8) with stage 5, and all the patients with stage 6
according to Ishak (Fig. 3). Stage 2 at 1-year biopsy
had 83% sensitivity and 87% speciﬁcity for the predic-
tion of clinical decompensation.
Cohort with HVPG Measurement
HVPG was measured in 89 of 135 patients (Table 3):
22 decompensated at a median time of 65 months
(12-146) and 18 patients died at a median of 61
months (14-157 months). This cohort was very similar
to the whole group without any signiﬁcant differences
in demographic or clinical data. In the univariate
analysis, we included the same variables listed in
Tables 1 and 2, but with the addition of HVPG. Uni-
variately, grade (P ¼ 0.001) and stage (P < 0.001)
according to Ishak, AHC (P ¼ 0.005) and CPA (P <
0.001), as well as HVPG (P ¼ 0.001) at 1-year biopsy
were associated with clinical decompensation. How-
ever, in the multivariate analysis by Cox regression,
only CPA independently predicted clinical decompen-
sation (P < 0.001; Exp(B) ¼ 1.158; 95%CI, 1.102-
1.217). The ROC curves of CPA, HVPG, and categories
of stage according to Ishak are shown in Fig. 4. The
area under the ROC curve of CPA for the prediction of
clinical decompensation was 0.962 (95%CI, 0.936-
0.994), of stage 0.877 (95%CI, 0.781-0.972), and of
HVPG 0.874 (95%CI, 0.790-0.959). At the cutoff value
of 6% of CPA, there was 95% sensitivity and 93%
speciﬁcity for the prediction of clinical decompensa-
tion. Kaplan-Meier curves of CPA  6% and CPA >
6% for this cohort with respect to the prediction of
decompensation are shown in Fig. 4.
Relationship Between CPA and HVPG
Previous ﬁndings suggested that CPA was a better
histological correlate with HVPG than Ishak stage,
showing greater numerical change when HVPG was
low (<6 mm Hg).12 Indeed in the current study, there
was a better relationship between CPA values and
Figure 2. Relationship between CPA values (box plots) and stage according to Ishak in the total cohort of 135 patients.
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HVPG compared to CPA and Ishak stage, with the
correlation coefﬁcient being r ¼ 0.612, P < 0.001.
With respect to clinical decompensation (Fig. 5),
only 1 of 62 patients decompensated with CPA  6%
(1.5%), whereas 21 of 26 (81%) patients decompen-
sated with CPA > 6%. Considering portal hyperten-
sion (HVPG > 6 mm Hg), 11.3% (8/70) of the patients
decompensated in the future when HVPG  6 mm Hg,
whereas 74% (14/19) decompensated when HVPG >
6 mm Hg at 1-year biopsy. Interestingly, when both
cutoff values were present (CPA > 6% and HVPG > 6
mm Hg), all of the patients above these cutoff points
decompensated (Fig. 5).
DISCUSSION
In this study, we retrospectively evaluated 135
patients with recurrent HCV, who underwent trans-
plantation between 1988 and 2008 and who survived
more than 12 months with a median follow-up of 76
months. We considered clinical decompensation as
the endpoint in our study, and we looked at factors
that could predict decompensation, comparing Ishak
scoring system, CPA, and HVPG measured at the
same time in biopsies at 1 year after transplantation.
We previously highlighted that quantitative assess-
ment of liver tissue collagen must be validated against
appropriate clinical outcomes and not histological
stage scores alone.1 In this study, as in our previous
studies, the amount of collagen was expressed as a
simple proportionate area that we believe is a more
representative method than that used in previous
studies of computer-assisted DIA,10,11,27 as we have
already previously noted.12
In this study, we showed that CPA measurement at
1 year post-LT was predictive of clinical decompensa-
tion in patients infected with HCV, with good sensitiv-
ity and speciﬁcity, which underscores the utility of a
quantitative approach to measure ﬁbrosis histologi-
cally. Univariately in the whole cohort, previous AHC,
Ishak grade and stage, and CPA at 1-year biopsy
were associated with clinical decompensation. The
presence of AHC suggests that severity of necroin-
ﬂammatory activity is related to rapid ﬁbrosis pro-
gression. Multivariately by Cox regression analysis,
CPA was a better discriminator for clinical
Figure 3. Relationship between CPA and Ishak stage with respect to prediction of future clinical decompensation.
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Figure 4. ROC curves of CPA, HVPG and categories of stage according to Ishak and Kaplan-Meier curves of CPA  6% and >6% with
respect to the prediction of clinical decompensation (chi-square 60.25, P < 0.001) in the cohort of 89 patients with recurrent HCV and
HVPG measurement, biopsied 1 year after liver transplantation. AUROC is 0.962 (95%CI, 0.936-0.994) for CPA, 0.877 (95%CI, 0.781-
0.972) for stage and 0.874 (95%CI, 0.790-0.959) for HVPG. At a cutoff value of 6% of CPA, there was 95% sensitivity and 93%
specificity for clinical decompensation and the highest Youden index.
TABLE 3. Characteristics of 89 Patients with HVPG Measurement Who Had
Liver Biopsies 1 Year After Liver Transplantation
Patients with HVPG
measured Decompensation (22) No Decompensation (67) P Value
Recipient Age 53 (21-65) 51 (33-66) NS
Males 68% 76% NS
Donor Age 44 (20-65) 40 (16-57) NS
Year of LT 88-94/95-00/
01-08 (%)
13.6%/32%/
54.4%
7.5%/25%/
67.5%
NS
Concomitant ALD % 13% 28% NS
Cold/warm ischemia Minutes 675/44 679/41 NS
Diabetes pre/post-LT % 18%/27% 20%/36% NS
Viral load pre-LT Median 2.54  106 1.88  106 NS
Viral load 1 year post-LT Median 4.2  106 2.9  106 0.1
Genotype 1 % 57% 47.5% 0.1
Patients treated N 13 19 NS
SVR (censored) 3 (23%) 6 (32%)
CMV infection % 23% 19% NS
Histological AHC % 64% 25% 0.005
ACR episodes 0/>2 36%/9% 10.6%/18% 0.01
Initial immunosuppression TAC/CYA/SIR 68%/32%/0%
(46% TAC mono)
79%/19%/1.5%
(36% TAC mono)
0.057
Steroids 50% 42% NS
AZA/MMF 45%/9% 52%/3% NS
Maintain immunosuppression TAC/CYA/SIR 59%/18%/23% 67%/15%/19% NS
Steroids 9% 1.5% NS
AZA/MMF 9%/18% 18%/21% 0.1
Follow-up months 72 (14-138) 76 (15-191) NS
Deaths n 10 8
Ishak stage 0-2/3-4/5-6 (%) 14/41/45 82/16/2 0.001
Ishak grade 0-6/7-12/13-18 (%) 62/33/5 95/5/0 0.001
CPA % median (range) 13.5 (3.4-36) 3.2 (0.20-10) 0.001
HVPG mm Hg median (range) 8.45 (3-16) 3.99 (1-10) 0.001
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decompensation than was Ishak stage. Indeed, there
was considerable overlap of CPA values for the indi-
vidual Ishak stages, as shown by the IQRs. At a cut-
off value of 6% of CPA, there was an 82% sensitivity
and 95% speciﬁcity for the prediction of clinical
decompensation, representing clinically useful thresh-
olds. Two other studies have also shown a relation-
ship of liver collagen to outcomes. Goodman et al.
measured collagen morphometrically in 535 patients
randomized in the HALT-C (Hepatitis C Antiviral
Long-Term Treatment Against Cirrhosis) trial over a
period of 5 years,27 but only in relation to long-term
pegylated interferon in nonresponders and relapsers
and not to clinical outcomes. In 53 children with bili-
ary atresia, liver collagen at the time of a Kasai opera-
tion was a predictive marker of transplant-free sur-
vival.28 It is well established that HVPG has
prognostic value in HCV-infected patients who under-
went transplantation.29-31 An HVPG threshold of
approximately 10 mm Hg deﬁnes clinically signiﬁcant
portal hypertension.32,33 CPA in the cohort (89
patients) with HVPG measurement (Fig. 4) had a bet-
ter AUROC than HVPG with respect to decompensa-
tion. CPA at the cutoff value of 6% showed a 95%
sensitivity and 93% speciﬁcity. Importantly, better
precision was obtained when CPA was combined with
HVPG for the prediction of clinical outcome, because
all patients with CPA > 6% and HVPG > 6 mm Hg at
1-year biopsy eventually decompensated (Fig. 5).
Several studies in the past have addressed the issue
of clinical outcome in HCV-infected patients after
transplantation, focusing on the identiﬁcation of fac-
tors that were associated with worse recurrence of
HCV.34-38 Factors associated with more aggressive
disease recurrence were immunosuppression regi-
mens17,34,39-44 and more recently treatment with TAC
monotherapy compared to triple therapy with TAC,
AZA, and steroids.26 Other factors have included CMV
infection,45-47 HCV viral load and genotype,42,48-50 do-
nor age,41,49-51 and a hepatitis ﬂare.17,26 Our current
results are consistent with our previously published
ﬁndings,17,26 because the occurrence of AHC in the
graft and TAC monotherapy were signiﬁcant in the
univariate analysis. However, all of the above studies
including ours16,25 are based on categorical descrip-
tive scoring systems to grade/stage of disease recur-
rence without reference to quantitative changes in
liver collagen.
Figure 5. Relationship between CPA and HVPG values with respect to prediction of clinical decompensation in 89 patients with
recurrent HCV who were biopsied 1 year after liver transplantation.
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The clinical signiﬁcance of ﬁbrosis in 1-year biopsy
in HCV-infected patients who have undergone LT has
been established by other groups48,50,52,53 and more
recently by Gallegos-Orozco et al.35 Patients with
moderate ﬁbrosis had worse outcome than patients
with minimal or absent ﬁbrosis. In our study, each
Ishak stage category correlated with a range of CPA
values, leading us to conclude once again12 that CPA
could have additional individual prognostic value
within each disease stage (Fig. 2).
In conclusion, in the current study, we conﬁrmed at
a single time point the good correlation between CPA
and HVPG which had been shown previously over
time.12 More importantly, we demonstrated for the ﬁrst
time that CPA was a good discriminator for clinical
decompensation, when measured in 1-year biopsies in
our cohort, and was a better discriminator than HVPG
or Ishak stage. CPA predicted subsequent clinical out-
comes and importantly gave added precision when
combined with HVPG. Thus, CPA can be considered as
the reference histological index for ﬁbrosis in future
studies in HCV-infected patients after LT, because it is
both a quantitative and continuous measure of ﬁbro-
sis. We believe it is a better reference standard to com-
pare with noninvasive indices of ﬁbrosis. However, fur-
ther studies are needed to validate the signiﬁcance of
CPA measurement in other liver diseases and in the
pretransplant setting for chronic hepatitis C.
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